– Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – – First and Only Treatment That Achieved ...

That brand is more than just a logo - it’s ... as B2C firms do. Some pharmaceutical brands are even experimenting with influencers, including a recent campaign from Gilead Science.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Hookipa Pharma (HOOK – Research Report) on February 28 and set a price target of ...

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...

When asked about each segment of ESG, almost all of the surveyed groups, 94%, said that the impact a pharma has on society ... followed by Gilead Sciences and Johnson & Johnson Innovative Medicine.

Still, Gilead kept an interest in Arcus' work, with the Foster City, California-based pharma plugging a further $320 million into its biotech partner at the time. Arcus said last year that it ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...